Bryan Picou, MD
Family Medicine · Natchitoches, LANPI 1174969133
Payments from drug & device makers
Across 211 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$422
- AstraZeneca$374
- Pfizer$327
- Merck$256
- Boehringer Ingelheim$229
- Novo Nordisk$195
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,518100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $422 |
| AstraZeneca | 23 | $374 |
| Pfizer | 20 | $327 |
| Merck | 18 | $256 |
| Boehringer Ingelheim | 15 | $229 |
| Novo Nordisk | 13 | $195 |
| GSK | 11 | $182 |
| Astellas Pharma US Inc | 13 | $181 |
| Xeris Pharmaceuticals, Inc. | 7 | $133 |
| Sumitomo Pharma America, Inc. | 5 | $112 |
| Kerecis Limited | 1 | $93 |
| Sanofi-aventis U.S. LLC | 6 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| Amarin Pharma, Inc. | 5 | $78 |
| Bayer | 4 | $76 |
| Novartis | 5 | $69 |
| Ultragenyx Pharmaceutical Inc. | 1 | $67 |
| Exact Sciences | 3 | $51 |
| Acera Surgical, Inc. | 1 | $49 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| AbbVie(2 entities) | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Amgen | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $27 |
| Convatec Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Medicure Pharma Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$3,518 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $116,328 |
| JardianceEmpagliflozin | 152 | $113,899 |
| FarxigaDapagliflozin Propanediol | 101 | $101,707 |
| Enbrel SureclickEtanercept | 13 | $100,025 |
| EliquisApixaban | 144 | $82,932 |
| TrulicityDulaglutide | 56 | $52,934 |
| MounjaroTirzepatide | 41 | $50,485 |
| RexultiBrexpiprazole | 64 | $46,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $40,337 |
| RybelsusSemaglutide | 28 | $30,205 |
| MyrbetriqMirabegron | 62 | $26,933 |
| JanuviaSitagliptin Phosphate | 39 | $24,843 |
| LinzessLinaclotide | 27 | $21,825 |
| XareltoRivaroxaban | 26 | $19,376 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $18,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $195 | $146,534111 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $229 | $127,720166 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $422 | $103,41997 claims |
| AstraZenecaFarxiga | $374 | $101,707101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Arexvy | $182 | $87,485169 claims |
| PfizerEliquis | $327 | $82,932144 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $46,06664 claims |
| Astellas Pharma US IncMyrbetriq | $181 | $26,93362 claims |
| MerckJanuvia | $256 | $24,84339 claims |
| AbbVieLinzess | $47 | $21,82527 claims |
| Johnson & JohnsonXarelto | $27 | $19,37626 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $112 | $13,13124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Natchitoches
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.